FDA issues an Emergency Use Authorization (EUA) for anakinra (Kineret) to treat Hospitalized COVID-19+ Patients with pne

Article Drug Safety

Don't Hold the Biologic or JAK with COVID-19 Vaccination

Jack Cush, MD Oct 8, 2026

A randomized clinical trial in inflammatory arthritis arthritis shows that temporarily holding biologic or Janus kinase (JAK) inhibitor therapy at the time of COVID-19 vaccination is not warranted.

Article Psoriatic Arthritis

FDA Approves Tildrakizumab for Psoriatic Arthritis

Jack Cush, MD Nov 2, 2026

Sun Pharmaceuticals announced Friday that the FDA has approved its IL-23 inhibitor, tildrakizumab (Ilumya) for use in patients with active psoriatic arthritis. This agent is already FDA approved for plaque psoriasis, and joins guselkumab and risankizumab as the third IL-23 inhibitor approved…

Article JAK/TYK2

TYK2 Inhibitor Deucravacitinib FDA Approved for Psoriatic Arthritis

Jack Cush, MD Mar 9, 2026

On Friday, March 6th, the FDA approved deucravacitinib (Sotyktu) for the treatment of adults with active psoriatic arthritis (PsA) based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials. Deucravacitinib, an oral selective tyrosine kinase 2 (TYK2) inhibitor, is the…